Stockwinners Market Radar for October 08, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:47 EDT PS Business Parks sells 3 business parks in Maryland for $148.8M - PS Business Parks announced that on October 8, 2019 it completed the sale of three business parks located in Montgomery County, Maryland: Metro Park North, Meadow Business Park and WesTech Business Park. The parks, consisting of 28 buildings totaling approximately 1.3M square feet, sold for a gross sales price of $148.8M. The company retained one single-tenant government building totaling 113,000 square feet and a long-term ground lease at Metro Park North.

19:00 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: FireEye (FEYE) up 4.8% after positive Q3 revenue pre-announcement. ALSO HIGHER: Just Energy (JE) up 4.3% after sale of UK unit, NA cost reduction initiative... LexinFintech (LX) up 2.5% after being initiated with Outperform at Credit Suisse... Peloton (PTON) up 0.4% after being initiated with Outperform at Baird. DOWN AFTER EARNINGS: Levi Strauss (LEVI) down 2.4%. ALSO LOWER: U.S. Steel (X) down 1.6% after announcing resignation of CFO... Johnson & Johnson (JNJ) down 1.5% after Reuters report of $8B punitive damages award in Risperdal case. Movers as of 18:45ET.

18:53 EDT Allegiant Travel reports September total system traffic down 0.5% - Reports September total system capacity down 3.7%. Reports September total system departures down 0.4%.

18:25 EDT Domino's Pizza CEO: We have a terrific business model - In an interview on CNBC's Mad Money, Domino's Pizza CEO Richard Allison Jr. said: This is a terrific cash flow business model... We generate over $1M in free cash flow per day... We've tightened up around G&A and CapEx which should improve margins... There is some irrational pricing in the third party delivery marketplace being funded by venture capital... 6% retail sales growth in U.S. is much faster than the restaurant industry... This is a great time for us in China... We have a lot of great things in the pipeline.

17:44 EDT Argo Group gets SEC subpoena over perquisite disclosures - Argo Group International Holdings confirmed that its independent directors are conducting a review of governance and compensation matters. The company also announced that it previously received a subpoena from the U.S. Securities and Exchange Commission seeking documents primarily with respect to the company's disclosure of certain compensation-related perquisites. The company, working with the assistance of outside counsel, is fully cooperating with the SEC and does not believe that the amounts involved are material to the company's financial position or results of operations.

17:41 EDT Granite awarded $37M interstate expansion project in Wisconsin - Granite announced that it has been awarded a $37M sub-contract by I-39 Constructors to construct a portion of the I-39/90 Expansion Project in Beloit, Wisconsin. Granite's scope of work includes the reconstruction of the I-39/90 and I-43/WIS 81 interchange and the I-39/90 southbound bridge over the Canadian Pacific Railroad. This section of work is part of the larger reconstruction and expansion of approximately 12 miles along I-39/90 from the Illinois state line north to County O, south of Janesville. The I-39/90 Expansion Project is part of a $1.2B multi-year investment by Wisconsin Department of Transportation to expand the Interstate in south-central Wisconsin. The project extends approximately 45 miles along Interstate 39/90 from the Illinois state line to the US 12/18 interchange near Madison, Wisconsin. Construction of Granite's contract is scheduled to begin in fall 2019 and will be complete by winter 2021.

17:32 EDT Franklin Resources reports preliminary AUM $692.6B as of September 30 - Compared to $690.6B at August 31. The increase in assets under management was due to market gains that more than offset net outflows. Preliminary average assets under management for the quarter ended September 30 were $702B.

17:04 EDT Methanex restructures natural gas supply deal with Empresa Nacional del Petroleo - Methanex announced that it has restructured its existing commercial arrangements with Empresa Nacional del Petroleo for natural gas supply to underpin approximately 25% of Methanex's 1.7M tonnes of annual production capacity in Chile for a six year period from 2020 through 2025. This longer-term gas supply arrangement provides greater certainty for future gas volumes for our Chile operations and allows for ENAP to make further investments in its gas development activities. The company expects the gas supply, combined with commitments from other gas suppliers, to allow for up to a maximum of 75% of a two-plant operation or annual production of up to 1.3M tonnes and is optimistic that it can secure sufficient gas to underpin a full two-plant operation over the coming years.

17:03 EDT Fluor, JGC and Technip awarded contract by Mozambique Rovuma Venture - Fluor announced that a consortium of Fluor, JGC Corporation of Japan and TechnipFMC of France was awarded an engineering, procurement and construction contract by Mozambique Rovuma Venture for its Mozambique Rovuma Liquefied Natural Gas, or LNG, Phase 1 Project in Cabo Delgado, Mozambique with an immediate release of a limited notice-to-proceed. Fluor will book its portion of this work in the Q4.

16:40 EDT Lennar officer David Collins sells almost $900K in company shares - Lennar officer David Collins disclosed in a filing that he had sold 15,000 shares of company stock at an average price of $$59.50 per share on October 7. The total transaction value of the sale was $892,500.

16:32 EDT Twitter apologizes for using two-factor authentication data for ads - Twitter announced on its website, "We recently discovered that when you provided an email address or phone number for safety or security purposes (for example, two-factor authentication) this data may have inadvertently been used for advertising purposes, specifically in our Tailored Audiences and Partner Audiences advertising system...We cannot say with certainty how many people were impacted by this, but in an effort to be transparent, we wanted to make everyone aware. No personal data was ever shared externally with our partners or any other third parties. As of September 17, we have addressed the issue that allowed this to occur and are no longer using phone numbers or email addresses collected for safety or security purposes for advertising. We're very sorry this happened and are taking steps to make sure we don't make a mistake like this again." Reference Link

16:31 EDT FMC Corporation announces new sustainability goals for 2025 and 2030 - FMC Corporation announced new sustainability goals for 2025 and 2030. The company's new goals include continued focus on the United Nations Sustainability Development Goals with emphasis on Zero Hunger and Life on Land. "FMC has made tremendous progress in defining, and in many instances, exceeding ambitious goals to advance the company's sustainability profile since our first goals were announced in 2015," said Linda Froelich, director of Corporate Sustainability at FMC. "With increasing threats from climate change, it is critical that we focus on ways to help mitigate the impacts of unpredictable weather patterns, rising sea levels and increasing global mean temperatures, which can all have a long-term impact on our business." The new FMC sustainability goals include dedicating 100 percent of R&D spend to developing more sustainable products, achieving 100 on the Community Engagement Index that measures interactions with the communities where we work and live, and attaining less than 0.1 Total Recordable Incident Rate (TRIR) across the organization, all by 2025. The goals also include improving the company's environmental footprint by 2030 through 25 percent reductions in energy and greenhouse gas emissions intensities, 20 percent reduction in water use intensity at high-risk locations, and maintaining waste intensities that would otherwise increase by 55 percent due to expected growth and shifts in product mix.

16:27 EDT Cerner CEO unveils next-generation cognitive platform - During his keynote at Cerner Health Conference, the company's Chairman and CEO, Brent Shafer, unveiled a next-generation cognitive health platform, introduced new tools that allow the company's clients to get more from Cerner technology, announced new predictive modeling built directly into the opioid toolkit and opened up free access to the company's training modules. "Health care will change more in the next five years than it has in the past 30," Shafer told an audience of 5,000 clients, innovators and other health care industry professionals during the keynote address. "As we have for the past four decades, Cerner's technology, and collaborative programs, along with the most respected providers, will lead a wave of disruptive innovation focused on making health care better." Aligning with the conference's theme of Now / Next, Shafer shared enhancements to benefit Cerner clients today [NOW], then announced a NEXT-generation health platform. Code named "Project Apollo," this initiative brings a more cognitive approach to practicing medicine. Leveraging the powerful combination of its health care technology and the AWS infrastructure, Cerner's new cloud-based platform will accelerate the speed that innovations are integrated by removing manual steps for clients that slow the pace of adoption. Additionally, Cerner is creating an intelligence ecosystem to innovate next-generation user experiences and care delivery algorithms. This future innovation will support caregivers in giving their full focus to delivering high quality, patient-centric care, supported by the power of Cerner's intelligent platform.

16:22 EDT Middlesex Water subsidiary receives approval to acquire Wilkerson Water - Middlesex Water Company announced that its subsidiary, Tidewater Utilities has received approval from the Delaware Public Service Commission, or DEPSC, to acquire the Wilkerson Water Company and the Broadkiln Beach Water Company, both in Delaware, from J.H. Wilkerson & Son, Inc. Customers of these companies will be served by Tidewater's regulated water utility business that currently serves more than 47,000 accounts throughout Delaware. The DEPSC approval also authorizes Tidewater to maintain the existing rates the Wilkerson and Broadkiln customers currently pay.

16:21 EDT Ophthalmology and Therapy data show Glaukos iStent Inject w/ more IOP reduction - Glaukos announced that an independent, international case series published in Ophthalmology and Therapy showed that iStent inject Trabecular Micro-Bypass System achieved a greater absolute intraocular pressure reduction and a higher medication-free rate at one year postoperative, compared to the first-generation iStent Trabecular Micro-Bypass Stent. All subjects in the case series received stents in combination with cataract surgery. This real-world retrospective case series included 137 eyes with cataract and mild-to-moderate glaucoma or ocular hypertension. More than 73% of eyes in both groups were in early states of glaucoma disease progression and approximately 22% had prior glaucoma surgery. All procedures were performed by David Manning, MD, at a single practice in Australia. Consecutive patients received either iStent inject or iStent, based on availability in the Australian market. At one year postoperative, mean IOP in eyes receiving iStent inject decreased 1.8 mmHg more than iStent eyes, based on the decrease in absolute IOP for each group. In addition, 92.9% of iStent inject eyes were medication-free at one-year postoperative, vs. 76.1% for the iStent eyes. The safety profile was favorable in both groups, with few adverse events and no secondary glaucoma surgeries.

16:17 EDT International Paper raises annual cash dividend 2.5% to $2.05 per share - International Paper declared a quarterly dividend of 51.25c per share for the period from October 1 to December 31, inclusive, on its common stock, par value $1.00. This dividend is payable on December 16 to holders of record at the close of business on November 15.

16:14 EDT Cohen & Steers reports preliminary AUM $70.8B as of September 30 - An increase of $1.3B from assets under management at August 31. The increase in assets under management from August 31 was due to market appreciation of $931M and net inflows of $613M, partially offset by distributions of $275M.

16:07 EDT IAA expands Davenport, IA branch inventory - IAA announces increased capacity of its Davenport, Iowa, branch. This investment increases the branch's inventory space by more than 20%. The IAA Davenport branch is one of two IAA branches in Iowa.

16:06 EDT Cardiovascular Systems discloses first patient treated with Stealth 360 OAS - Cardiovascular System announced that the first patient in the United Arab Emirates has been treated with its Stealth 360(R) Peripheral Orbital Atherectomy System, or OAS. The first peripheral patient in the Middle East was treated by Dr. Faisal Hasan at the Cleveland Clinic Abu Dhabi, UAE.

15:04 EDT Lennar subsidiary acquires Charlotte apartment community - LMC, a wholly owned subsidiary of Lennar (LEN), announced its acquisition of Novel Stonewall Station, a luxury transit-oriented apartment community located in Uptown, a Charlotte submarket. The transaction marks LMC's first acquisition of an existing multifamily community.

14:15 EDT Medtronic recalls 6 French Sherpa NX catheters over fragmentation issue - Medtronic is recalling the 6 French Sherpa NX Active Guide Catheter due to a risk of the outer material separating from the device resulting in detached fragments that could result in the underlying stainless-steel braid wires being exposed, according to the FDA. These fragments could be left inside the patient's bloodstream, and this or the attempts made to retrieve the fractured pieces, can cause other serious adverse health consequences such as continued blockage of blood vessels, injury to blood vessel walls, development of blood clots, embolism, heart attack or death. Medtronic received five customer complaints. No serious injuries or deaths were reported.

13:54 EDT FDA acknowledges receipt of citizen's petition regarding Makena - Dynna Bigby, Supervisory Administrative Proceedings Officer for the FDA Office of Operations, stated in a letter posted to the Regulations.gov website that a petition to the Commissioner of Food and Drug Administration requesting that the FDA immediately withdraw approval of all medications containing hydroxyprogesterone caproate, which is currently marketed under the brand name Makena and multiple generic formulations, was received by the office on October 8, 2019. The letter states: "Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition." Amag Pharmaceuticals markets the Makena autoinjector. Reference Link

13:22 EDT Apollo Medical down 13% to $13.78 in afternoon trading - Shares of Apollo Medical are down $2.05, or 12.95%, to $13.78 in afternoon trading. According to trading contacts, the weakness is being attributed to an announcement from FTSE Russell regrading an index that includes the stock.

13:02 EDT FS Bancorp raises quarterly dividend 33% to 20c per share - FS Bancorp announced that its Board of Directors declared a regular quarterly cash dividend of 20c per common share, payable on November 15, 2019 to holders of record as of November 1, 2019. The 20c cash dividend represents an increase of 33% from the 15c cash dividend paid during first, second and third quarters of 2019.

12:42 EDT Microsoft's Xbox One updates family settings, wish list settings and Mixer - Jason Ronald, Director of Program Management for Xbox Platform Posted on Xbox Wire earlier on Tuesday: "October is here and we know many gamers are already spending quality time with their favorite horror games, we won't judge if you turn the brightness up,. But never fear, we're here to share lots of new features and improvements with the October 2019 Xbox One Update, which begins rolling out to everyone today. This month's update unveils new Family Settings options to balance your family's screen time, Wish List notifications, improvements to the Mixer viewing experience on Xbox One, the ability to refer Xbox Game Pass titles to friends, and even more improvements based on your feedback. Read on for a breakdown on each new feature and update." Reference Link

12:14 EDT Herman Miller to acquire additional 34% equity interest in HAY A/S - Herman Miller announced it signed an agreement to acquire an additional 34% equity interest in HAY A/S for approximately $78M. This transaction follows a similar transaction in 2018 in which Herman Miller acquired a 33% equity interest in HAY. Upon closing the current transaction, Herman Miller will own a majority 67% interest in HAY; Rolf and Mette Hay, Co-founders and Creative Directors of HAY, own the remaining 33% of the equity in HAY. Upon closing the transaction, Herman Miller expects to consolidate HAY's operating results going forward and record a non-controlling interest for the remaining 33% minority ownership stake. Revenue for HAY's most recent fiscal year that ended in July 2019 totaled approximately $160M. Excluding the potential purchase accounting impact related to a required step-up in inventory carrying value, this transaction is expected to have a 1c-2c accretive impact on earnings per share in the second half of FY20. Herman Miller currently expects the acquisition to close December 2, subject to the satisfaction or waiver of certain customary closing conditions.

12:00 EDT AZZ Inc. falls -14.3% - AZZ Inc. is down -14.3%, or -$6.17 to $36.84.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 5.9% - Daily S&P Biotech Bear 3x Shares is up 5.9%, or $1.46 to $26.35.

12:00 EDT ProShares Trust Ultra VIX Short Term Futures ETF rises 7.8% - ProShares Trust Ultra VIX Short Term Futures ETF is up 7.8%, or $2.10 to $28.95.

11:24 EDT Altisource announces wind down, closure of Owners.com - Altisource Portfolio Solutions announced that it decided to wind down and close Owners.com's operations. The Company believes that closing Owners.com supports its simplification strategy, eliminates the cash burn associated with this earlier stage business, and increases focus on the core real estate and mortgage businesses. During the six months ended June 30, 2019, Owners.com generated $3.8M of revenue and $8.1M of loss before income taxes. In connection with the exit of the Owners.com business, the Company estimates that it will recognize a $5.9M non-cash goodwill and intangible assets impairment charge in the fourth quarter of 2019 as well as wind-down and severance costs.

11:08 EDT Boeing says has delivered 302 aircraft YTD, including 113 787s

11:03 EDT Boeing reports Q3 total deliveries of 63, 302 deliveries YTD

10:59 EDT FTE Networks Inc trading halted, news pending

10:26 EDT Ansys announces agreement with Motor Design Limited - Ansys announced earlier today an agreement with Motor Design Limited to distribute Motor-CAD. "From electric and hybrid propulsion in transportation to electric motor-driven systems in the industrial sector to the future of electric flight, the global demand for greater power efficiency is driving electrification initiatives across industries at a rapid pace. Designing more efficient electric machines and applying them in more applications reduces environmental impact and cost for consumers, companies and governments. The collaboration between ANSYS and MDL creates a comprehensive design methodology to support these applications and satisfy power efficiency requirements," the company said in a statement. Motor Design Limited's software, Motor-CAD, enables design engineers to evaluate motor topologies and concepts across the full operating range and to produce designs.

10:06 EDT Procter & Gamble names Disney CFO Christine McCarthy to board - The Procter & Gamble Company (PG) announced that at its 2019 Annual Meeting of Shareholders, Christine M. McCarthy was newly elected to its Board of Directors, effective immediately. P&G shareholders elected all 12 P&G Directors, including McCarthy and 11 incumbent Directors, according to preliminary voting results. McCarthy has served as Senior Executive Vice President and CFO of The Walt Disney Company (DIS since 2015, where she oversees the company's worldwide finance organization, which includes brand and franchise management, corporate alliances, corporate real estate, corporate strategy, enterprise controllership, enterprise social responsibility, enterprise technology, financial planning and analysis, global product and labor standards, investor relations, risk management, tax, and treasury.

10:01 EDT Medtronic gets FDA Breakthrough Designation for Valiant TAAA Stent Graft System - Medtronic announced it has received Breakthrough Device designation from the U.S. FDA for its Valiant TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm. A TAAA is a complex condition causing a bulging of the aorta, which extends from the chest down into to the abdomen.

10:00 EDT AZZ Inc. falls -13.6% - AZZ Inc. is down -13.6%, or -$5.84 to $37.17.

10:00 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 5.1% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 5.1%, or $3.24 to $66.95.

10:00 EDT ProShares Trust Ultra VIX Short Term Futures ETF rises 6.1% - ProShares Trust Ultra VIX Short Term Futures ETF is up 6.1%, or $1.64 to $28.49.

09:47 EDT AZZ Inc. falls -7.0% - AZZ Inc. is down -7.0%, or -$3.01 to $40.00.

09:47 EDT Leaf Group rises 5.1% - Leaf Group is up 5.1%, or 17c to $3.49.

09:47 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 5.6% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 5.6%, or $3.59 to $67.30.

09:22 EDT Cocrystal Pharma presents data from drug design platform technology - Cocrystal Pharma announced that Sam Lee, Ph.D., President of Cocrystal, presented positive data from its unique structure-based drug design platform technology at the 26th International Symposium on Hepatitis C Virus and Related Viruses Conference being held on October 5-8, 2019 in Seoul, South Korea. As part of his poster presentation, Dr. Lee provided an overview of the Company's proprietary structure-based drug discovery technology which has demonstrated the ability to design and develop a high barrier to drug resistance and to be a highly potent, selective non-nucleoside inhibitor (NNI) that is active against all HCV genotypes with low level cytotoxicity in multiple cell types. Cocrystal has applied its proprietary platform technology to develop CC-31244, an investigational, oral, broad-spectrum replication inhibitor or NNI, to have a high barrier to drug resistance and to be a highly potent, selective NNI that is active against all HCV genotypes with low level cytotoxicity in multiple cell types. In January 2019, the Company announced safety and preliminary efficacy data from its triple regimen, U.S. Phase 2a study evaluating CC-31244 and Epclusa for the ultra-short treatment of HCV infected individuals. Additionally, CC-31244 is being evaluated in a Phase 2a study in Hong Kong SAR, China.

09:17 EDT Adamis Pharmaceuticals announces presentation of ZIMHI data - Adamis Pharmaceuticals announced the presentation of data pertaining to its investigational high dose naloxone product at the Institute of Human Virology meeting in a session on "Opioid Intersection". Other participants at the meeting included Dr. Robert Gallo, Co-Founder and Director, Institute of Human Virology, Dr. Nora Volkow, Director, National Institute of Drug Abuse, National Institutes of Health, and Admiral Brett Giroir, MD, Assistant Secretary for Health, US Department of Health and Human Services. The Adamis data was presented by Dr. Ronald Moss, Chief Medical Officer at Adamis. Naloxone is an opioid antagonist that competes opioids off their receptors in the brain. Rapid and efficient reversal by naloxone is critical as brain injury and death can occur within minutes. Adamis presented data comparing the pharmacokinetics of ZIMHI to current doses of naloxone products. ZIMHI had significantly higher and more rapid levels of naloxone in the blood compared to the other products. Adamis also presented data on a model that simulated various overdoses due to the more potent synthetic opioids such as fentanyl. ZIMHI was shown in the model to rapidly compete out fentanyl from the receptors in the brain while current doses took longer. The model suggested that at higher doses of fentanyl overdose, higher doses of naloxone, such as are contained in ZIMHI, can potentially result in a more rapid and successful resuscitation.

09:13 EDT NXP Semiconductors, ART partner for infotainment systems for sports cars - NXP Semiconductors and ART SpA, have joined forces to create an immersive infotainment systems for luxury sports cars that are synonymous with speed, power, and exclusivity. ART is designing its ARTIST 8 Development platform for infotainment systems with NXP's i.MX 8QuadMax applications processors. The infotainment system provides in-vehicle entertainment features, including smartphone integration, making them easy and safe to use. Car occupants have complete control of multimedia, plus the ability to access off-line and connected content and manage vehicle comfort functions. The NXP i.MX 8QuadMax applications processor powering the ARTIST 8 infotainment system from ART is slated to be incorporated into 2021 vehicle production.

09:08 EDT Aviat Networks' WTM 4800 platform selected by Globe Telecom - Aviat Networks announced that Globe Telecom will deploy its WTM 4800 E-band and multi-band radio platform to support their 5G rollouts. WTM 4800 is the industry's first and only single box, multi-band solution which lowers total cost of ownership, or TCO, significantly, compared to alternative multi-band solutions. Globe will also use the Aviat Design tool for multi-band link planning, allowing the provider to simplify network planning of multi-band links. Additionally, Globe will be leveraging Aviat's NETCONF/YANG interfaces to support its automation and software defined networking initiatives, the result of close collaboration between the companies.

09:06 EDT Carl's Jr. announces new Beyond BBQ Cheeseburger - Carl's Jr. is expanding its partnership with Beyond Meat to launch "an innovative new menu item" - the Beyond BBQ Cheeseburger - available at participating restaurants beginning October 9. "Drawing on the success of its Beyond Famous Star, the restaurant developed a new burger build meant to complement the Beyond Burger patty, while drawing on the flavors of its famed Western Bacon Cheeseburger."

09:05 EDT RCI Hospitality reports Q4 SSS up 11.8% vs last year - RCI Hospitality Holdings announced total and same-store sales for its Nightclubs and Bombshells restaurants for the Q4 and FY19. 4Q19 vs. 4Q18 highlights include total club and restaurant sales $44.0M compared to $39.4M, up 11.8%; consolidated same-store sales $38.0M compared to $37.4M, up 1.5%; Nightclubs total sales, $35.5M compared to $33.8M, 4.9%; nightclubs same-store sales $32.6M compared to $32.9M, down 0.9%; bombshells total sales $8.5M compared to $5.5M, up 53.9%; and bombshells same-store sales $5.3M compared to $4.5M, up 19.4%. FY19 vs. FY18 highlights include: total club and restaurant sales $177.8M compared to $163.0M,up 9.1%; consolidated same-store sales $154.9M compared to $155.4M, down 0.3%; and nightclubs total sales $146.9M compared to $138.9M, up 5.8%

09:03 EDT Streamline Health names Wyche T. Green as president and CEO - Streamline Health Solutions announced that Wyche T. "Tee" Green, III has assumed the role of President and CEO on a full-time basis. Accordingly, the company has cancelled its search for a new President and CEO. Green is currently Chairman of the Board of Directors of Streamline Health and will continue in that capacity, adding the role of President and CEO with the objective of driving the company's improved performance, primarily in the area of accelerating sales of its compelling eValuator automated pre-bill coding analysis technology. "Back in July when I accepted the Interim President and CEO role, I said I wanted to help intensify our focus on a sales and marketing strategy to grow revenue while delivering an exceptional customer experience," stated Green. "Having spent the last two months working more closely with the leadership team and meeting with executives at some of our key clients, I am more convinced than ever that our eValuator product can be the leading solution in our industry's movement to analyzing the coding of all patient records before they are sent to billing. I've seen opportunities like this before and firmly believe I can help this company achieve the objectives we have set since I took on the Interim President and CEO role."

09:01 EDT VistaGen Therapeutics completes dosing of last patient in Elevate Phase 2 study - VistaGen Therapeutics announced that the last patient has completed dosing in the ELEVATE Phase 2 clinical study of AV-101, the Company's novel, oral NMDA, or N-methyl-D-aspartate, receptor glycine site antagonist, as an adjunctive, or add-on, treatment with an FDA-approved oral antidepressant for major depressive disorder. The Company remains on track to report top line results of the ELEVATE study before the end of 2019.

08:56 EDT Aphria says 'disappointed' Aleafia terminated supply agreement - Aphria issued the following statement in regards to Aleafia Health's termination of the company's wholesale cannabis supply agreement with Emblem Corp: "We are disappointed that Aleafia has chosen to terminate its Agreement with Aphria Inc. The company had every intention of fulfilling its obligations under the Agreement. As a large shareholder of Aleafia, Aphria made good faith efforts to ensure continuation of the Agreement understanding it was in the best interest of all parties involved. However, the termination of this legacy Agreement frees up significant supply allowing the company to service its brands that are in high-demand across the country." The Parties are contractually obligated to negotiate for a period of 30-days following the receipt of a formal notice of termination. If the Parties fail to arrive at any agreement or settlement within the 30-days, and if Aleafia initiates a formal claim for damages, the company intends to vigorously defend itself. The Agreement is not a material part of the company's business and operations.

08:51 EDT Fly Intel: Pre-market Movers - UP AFTER EARNINGS: Helen of Troy (HELE), up 5%. ALSO HIGHER: NIO Inc. (NIO), up 12% after reporting that the company delivered 4,799 vehicles in Q3, increasing 35.1% from Q2 and exceeding the middle point of the company's guidance range. DOWN AFTER EARNINGS: Domino's Pizza (DPZ), down 5%. ALSO LOWER: Qiagen (QGEN), down 20% after the company announced that its long-standing CEO Peer Schatz is resigning, Q3 results are below expectations, and it will partner with Illumina (ILMN) on NGS-based IVD kits... Ambarella (AMBA), down 14% following reports that the 28 Chinese companies added to the U.S. entity list includes two of the company's customers, HIKVision and Dahua... Nektar Therapeutics (NKTR), down 6% after Goldman Sachs analyst Paul Choi double downgraded the stock to Sell from Buy with a price target of $16, down from $54... Boeing (BA), down 1% after The Wall Street Journal reported that the European Union Aviation Safety Agency recently told senior U.S. regulators it wasn't satisfied that FAA and Boeing officials had adequately demonstrated the safety of reconfigured MAX flight-control computers. Also, a union of Southwest Airlines (LUV) pilots announced last night that it has filed a lawsuit against Boeing for "deliberately misleading the organization and its pilots about the 737 MAX aircraft."

08:44 EDT ElectraMeccanica announces financing agreement with FreedomRoad Financial - ElectraMeccanica Vehicles Corporation has entered into an agreement with FreedomRoad Financial to provide consumers with vehicle financing for the company's flagship SOLO electric vehicle. The SOLO EV is a single-seater electric vehicle produced by Vancouver-based ElectraMeccanica. The SOLO features a 100-mile range, cruises comfortably at highway speeds and can charge on a regular household current, as well as public charge stations, in under 6 hours.

08:40 EDT Synchronoss Technologies secures working capital financing - Synchronoss Technologies announced that it has secured two working capital facilities to provide additional liquidity and flexibility as it continues to execute its growth objectives. The company has closed on a three-year $10M senior secured line of credit with Citizens Bank N.A. The proceeds of the line of credit will be used for general corporate purposes. The company has also entered a Supply Chain Financing program with Citibank N.A. The program enables the company to accelerate cash collections by selling receivables to Citibank on a non-recourse basis. The discount on the receivable sale is based on the strong credit ratings of our customers. Receivables from key customers will be included in the Citibank program, which is expected to provide, on average, between $15M and $20M of additional liquidity for the company.

08:38 EDT Exelixis discloses Paragraph IV notice from MSN Pharma on generic Cabometyx - In a regulatory 8-k filing released yesterday, Exelixis announced that it has received a Paragraph IV Certification Notice Letter from MSN Pharmaceuticals that MSN had filed an Abbreviated New Drug Application with the FDA for a generic version of CABOMETYX, or cabozantinib, tablets 20 mg / 40 mg / 60 mg. The Notice states that MSN intends to market a generic version of CABOMETYX before the expiration of Exelixis' U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, all of which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The Notice does not challenge the CABOMETYX composition of matter patent No. 7,579,473, which expires on August 14, 2026. Exelixis currently is reviewing the Notice. The company intends to vigorously enforce its intellectual property rights relating to CABOMETYX, but cannot predict the outcome of this matter. CABOMETYX is protected by six issued patents in the United States, all of which are listed in the Orange Book.

08:35 EDT Xenetic says working with KOLs, experts to formalize XCART development plan

08:35 EDT Xenetic says PolyXen expected to generate royalties as early as Q4

08:33 EDT Net 1 UEPS exercises option to acquire additional 35% of Bank Frick for $46.4M - Net 1 UEPS Technologies announced that it has exercised its option to acquire an additional 35% interest in Bank Frick & Co. for approximately $46.4M, subject to certain purchase price adjustments. The transaction is subject to approval from the Liechtenstein Financial Market Authority and is expected to close in March 2020. Following the successful completion of the additional investment, the Company will own 70% of Bank Frick with the Kuno Frick Family Foundation owning the remaining 30% interest. "Bank Frick provides the cornerstone of our European strategy to deliver all-encompassing financial technology and banking services to SMEs in the region," said CEO Herman Kotze. "The bank's strong CHF 90 million Tier 1 capital, Visa and MasterCard memberships, pan-European universal banking license and recognized leadership in banking services, especially to the virtual financial assets / crypto industry will meaningfully increase the breadth, scale and speed of complementary offerings of both Net1 and Bank Frick's fintech businesses. We are grateful to have the Frick family as co-shareholders and Dr. Mario Frick, in particular, as chairman of the board. We look forward to continue the excellent relationship that we have established over the last two years with the Frick family and the bank's executives and employees. We expect the transaction to be accretive to fiscal 2021 fundamental earnings."

08:33 EDT Global Payments announces integration with Samsung Pay - Global Payments (GPN) announced the technology behind its Netspend general purpose reloadable Mastercard has been integrated into Samsung's (SSNLF) digital wallet, Samsung Pay, and will drive its Samsung Pay Cash service. "Samsung smartphone users with Samsung Pay eligible devices will be able to access an auto-provisioned prepaid card called Samsung Pay Cash. This Netspend mobile-integrated digital Mastercard allows smartphone users to establish a digital prepaid card within their mobile wallet to hold funds for a variety of use cases, including spending and budgeting. The prepaid card also uses Mastercard token services that enable users to store and use the card without ever exposing card details to ensure safety for digital payments."

08:32 EDT DexCom announces FDA clearance of new Dexcom G6 Pro CGM - Dexcom announced the FDA has cleared the Dexcom G6 Pro Continuous Glucose Monitoring, or CGM, System for healthcare professionals to use with their patients, ages two years and up. "Dexcom G6 Pro is the first and only single use, professional CGM that gathers real-time glucose data over a 10-day period and offers both a blinded and unblinded mode. In blinded mode, real-time glucose data is hidden from the patient and reviewed retrospectively with their healthcare professional at the end of the session. In unblinded mode, patients can see their glucose data throughout the 10-day sensor wear to gain insights and make treatment decisions in real time."

08:31 EDT Neurotrope announces review of strategic alternatives - Neurotrope announced its plans to explore strategic alternatives to maximize shareholder value. "Following the results from our Phase 2 study of Bryostatin-1 in Alzheimer's disease, we believe a review of strategic alternatives is an important step toward preserving and enhancing shareholder value," stated Dr. Charles S. Ryan, Neurotrope's CEO. "The Board of Directors has formed a strategic alternatives committee to aid in evaluating the company's alternatives, and we look forward to providing an update when appropriate." There can be no assurance that the formal strategic review of alternatives will result in any successful transaction or other outcome. The company does not intend to comment further or publicly discuss the potential of alternate developments unless and until its Board of Directors has approved a definitive transaction, or otherwise determined that further disclosure is appropriate or required by law. Moreover, the company is continuing to determine how to proceed with respect to the company's current development programs for Bryostatin-1 in its effort to maximize shareholder value. As of August 7, the company had approximately $20.8M of cash and cash equivalents.

08:28 EDT VMware completes tender offer for Carbon Black common stock - VMware (VMW) and Carbon Black (CBLK) announced that VMware has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock, of Carbon Black for a price of $26 per share, net to the seller in cash, without interest and less any applicable withholding taxes. The Tender Offer expired at 5:00 p.m., New York City Time, on Monday, October 7, 2019 and was not extended. Approximately 64.1 million Shares of Carbon Black, representing approximately 85.1% of the outstanding Shares, were validly tendered in the Tender Offer and not validly withdrawn. All conditions to the Tender Offer were satisfied. All Shares of Carbon Black that were validly tendered and not validly withdrawn have been accepted for purchase.VMware will promptly complete its acquisition of Carbon Black through consummation of a merger of Calistoga Merger Corp., with and into Carbon Black without a vote of the Carbon Black stockholders, in accordance with Section 251(h) of the General Corporation Law of the State of Delaware. Each remaining Share of Carbon Black not purchased in the Tender Offer will be converted into the right to receive the same $26 in cash, without interest and less any applicable withholding taxes, that will be paid in the Tender Offer. Upon completion of the merger, Carbon Black will be a wholly-owned subsidiary of VMware. As a result of the acquisition, Shares of Carbon Black will cease to be traded on the Nasdaq Stock Market, effective today as of market open.

08:24 EDT Salarius adds MSKCC, Nationwide Children's as sites for Phase 1/2 trial - Salarius Pharmaceuticals announced that Memorial Sloan Kettering Cancer Center in New York City and Nationwide Children's Hospital in Columbus, OH have been added as clinical trial sites in the ongoing Phase 1/2 clinical trial of Seclidemstat for the treatment of Ewing sarcoma. The addition of MSKCC and Nationwide Children's brings the total number of active clinical trial sites to eight. The Phase 1/2 clinical trial of Seclidemstat in patients with relapsed or refractory Ewing sarcoma is an open-label dose escalation and dose expansion study to determine the maximum tolerated dose and establish the initial safety profile of Seclidemstat. The dose expansion portion of the study, or phase 2 portion, may provide potential efficacy data. In September, the Safety Review Committee cleared the third dose level, and the fourth dose level is currently enrolling. Based on current projections, Salarius expects to reach MTD in early 2020 and report initial patient data later in the same year. Study enrollment at Memorial Sloan Kettering will be led by Paul A. Meyers, M.D., Chief of Pediatric Sarcoma Service and Vice-Chair for Clinical Affairs. Study enrollment at Nationwide Children's Hospital will be led by Bhuvana A. Setty, M.D., Nationwide Children's principal investigator. In addition to MSKCC and Nationwide Children's, active clinical trial site locations include, Johns Hopkins All Children's Hospital in St. Petersburg, FL; Children's Hospital of Los Angeles in Los Angeles, CA; Moffitt Cancer Center in Tampa, FL; Dana-Farber Cancer Institute in Boston, MA; MD Anderson Cancer Center in Houston, TX; and the Sarcoma Oncology Center in Santa Monica, CA.

08:19 EDT Target teams with Toys"R"Us - Target and Tru Kids Brands, the proud parent of the Toys"R"Us brand, announced that Target's toy assortment, digital capabilities and fulfillment services will support the new online and in-store Toys"R"Us shopping experiences in the United States. Relaunching today, ToysRUs.com features content-rich videos and articles on the latest trends and hottest toy brands, in-depth product reviews, hot toy lists and brand experiences to help consumers find the perfect toys and gifts to delight kids of all ages. Consumers browsing toys on ToysRUs.com can click "Buy Now at Target.com" to be automatically linked to the same product page on Target.com to complete their purchase. Target.com will also power online sales in new Toys"R"Us experiential retail stores that will launch later this fall in Houston, Texas and Paramus, New Jersey. The stores are designed to showcase new products out of the box, and create memorable experiences for kids and families that allow for in-person product discovery. Guests interested in purchasing items not available in store will interact with sales associates who will assist them in completing sales transactions that will be fulfilled through Target.com.

08:16 EDT BeyondSpring announces publication of data on mechanism of plinabulin - BeyondSpring announced that Cell Press publications Chem and Cell Reports, two peer-reviewed scientific journals, published new data that sheds light on the mechanism of action of the Company's lead Phase 3 asset, Plinabulin, being developed in parallel for the treatment of cancer and prevention of chemotherapy-induced neutropenia. In the Chem article, titled, "Structure, Thermodynamics and Kinetics of Plinabulin Binding to Two Tubulin Isotypes," researchers utilizing x-ray crystallography and thermodynamics calculations demonstrated that Plinabulin as a NCE is differentiated from other tubulin-binding agents in both its binding site and the kinetics of the binding. The research also provides evidence that this binding may explain the beneficial efficacy and superior safety profile found with Plinabulin in the clinic, compared to other agents that bind to a nearby colchicine site in tubulin, such as C4AP or colchicine.

08:12 EDT Future Farm's Maine hemp farm completes state-mandated THC testing - Future Farm Technologies announced that hemp from the Company's farm in Hersey, Maine has passed the state-mandated testing for acceptable levels of THC. The results mean that the farm has cleared the last regulatory hurdle for harvest, which is planned for mid-October. Future Farm will next utilize independent laboratories to test the harvested hemp throughout the drying and curing processes.

08:10 EDT Cyclerion, collaborators to present research on sickle cell disease patients - Cyclerion Therapeutics announced upcoming medical meeting presentations highlighting its commitment to sickle cell disease patients and supporting its therapeutic approach to treating the disease through sGC stimulation. Cyclerion will present at the Annual National Convention of the Sickle Cell Disease Association of America, held October 9-12 in Baltimore, and at the Annual Sickle Cell Disease and Thalassaemia Conference, held October 21-23 in London. Cyclerion and its collaborators will present new research from a sickle cell disease patient journey project. This project was designed to improve understanding and characterization of common patient experiences from birth onward, including: initial diagnosis; first crisis and emergency room experiences; transition from pediatric to adult care; navigating personal milestones such as relationships, having children, and work responsibilities; and daily management of sickle cell disease. The research project was developed by a steering committee consisting of adult patients, caregivers of pediatric patients, and healthcare providers. In addition to the patient journey research, Cyclerion will present preclinical data on its investigational sGC stimulator olinciguat and an overview of its Phase 2 STRONG SCD study. Cyclerion is focused on unlocking the full therapeutic potential of the nitric oxide-cyclic guanosine monophosphate signaling pathway, a clinically validated pathway with potential for therapeutic applications in a wide range of cardiovascular, metabolic, inflammatory, fibrotic and neurological diseases. sGC is a key node in this pathway, and Cyclerion's targeted sGC stimulators are designed to enhance pathway signaling in the tissues of greatest relevance to the diseases each is intended to treat. Olinciguat is Cyclerion's investigational sGC stimulator designed to target the vasculature as well as organs with high blood flow, such as the kidney and lungs, which may make it well suited for the potential treatment of sickle cell disease.

08:08 EDT Omnicell announces partnership with Salem Health - Omnicell announced that Salem Health Hospitals & Clinics has partnered with Omnicell to improve safety and efficiency in their medication management processes through the company's automation and intelligence solutions at their flagship Salem Hospital, in Salem, OR. Salem Health will leverage Omnicell XT Automated Dispensing Cabinets, which are integrated with the hospital's electronic health record system to streamline workflows, improve nursing-pharmacy efficiency and help enhance patient safety. The Omnicell platform also offers closed-loop interoperability to provide advanced medication tracking and diversion prevention.

08:07 EDT Silicon Labs appoints Megan Lueders as Chief Marketing Officer - Silicon Labs (SLAB) announced Megan Lueders has joined the company as Chief Marketing Officer. With more than 20 years of high-tech executive experience, Lueders will lead the company's global marketing team responsible for reputation management, sales pipeline acceleration and customer experience. During her career, Lueders has built high-performance marketing teams at industry leaders like Zenoss, Lifesize, a Division of Logitech (LOGI), and Verizon (VZ) to accelerate growth and meet key businesses objectives.

08:07 EDT Progenics holder Velan Capital says 'new board immediately needed' - Velan Capital, one of the largest stockholders of Progenics Pharmaceuticals, announced that it has sent a letter to fellow Progenics stockholders and filed a definitive consent statement with the SEC in connection with its solicitation of written consents from stockholders to reconstitute the Progenics board through the removal of the three long-tenured directors and the election of five new, highly-qualified, fully-independent nominees. The letter states Velan believes a "reconstituted board is immediately needed to reverse strategic, operational and oversight failures at the company." The letter also states, Velan "believes the recently-announced Lantheus transaction massively undervalues the company and is a desperate attempt by current leadership to avoid accountability at all costs." Velan announced it will issue "a comprehensive plan outlining how Progenics can reach its potential and urges shareholders to vote the GREEN consent card."

08:04 EDT Sabre and eSky sign new distribution agreement - eSky and Sabre have signed a new distribution agreement that will power growth in new markets. Through Sabre, eSky will have access to content from more than 420 airlines, 750,000 hotels, and hundreds of tour operators, rail, car and cruise providers, enabling it to sell personalized travel packages from suppliers all over the world. eSky will benefit from Sabre's shopping technology, Bargain Finder Max.

08:02 EDT Amag Pharmaceuticals announces settlement agreement with Caligan Partners - AMAG Pharmaceuticals announced that it has entered into a settlement agreement with Caligan Partners. As part of this agreement, the Board of Directors has appointed Paul Fonteyne, former CEO of Boehringer Ingelheim USA, and David Johnson, Partner and co-Founder of Caligan, to the AMAG Board, effective immediately. The appointment of Fonteyne and Johnson temporarily expands the size of the AMAG Board to 11 directors, 10 of whom are independent and four of whom have been appointed within the past six months. In addition, the Company will include Fonteyne and Johnson as candidates in the Company's proxy statement for the Company's 2020 Annual Meeting. Following the 2020 Annual Meeting, the size of the Board will revert to nine directors. As part of this settlement agreement, Caligan has withdrawn its pending consent solicitation and agreed to a customary standstill, voting commitment, and related terms. The full agreement will be filed on Form 8-K with the U.S. Securities and Exchange Commission.

07:57 EDT Domino's Pizza down about 5% to $230.60 after Q3 results miss estimates

07:50 EDT Mayfield Pharmaceuticals to present on pipeline at SVB Leerink conference - Mayfield Pharmaceuticals, the women's health-focused subsidiary of Harrow Health, announced its CEO Melissa Bradford-Klu, will discuss Mayfield's advancements in developing new anti-infective medications such as its MAY-66 drug candidate for recurrent bacterial vaginosis, as well as Mayfield's programs for dyspareunia and interstitial cystitis, at the SVB Leerink New Treatments Focused on Women's Health Conference. Mayfield's drug candidate pipeline includes: MAY-66, which is a chemical entity drug candidate intended to prevent recurrent bacterial vaginosis. The company said, "MAY-66 has produced extraordinarily promising data in what we believe is a translatable pre-clinical model." Approximately 21 million women in the U.S. are estimated to suffer from BV and high reoccurrence rates of BV are an ongoing need. Complications of BV, if left untreated, include increased risk of acquiring and transmitting HIV, increased risk of preterm birth and reduction in fertility during IVF therapy. The addressable market for MAY-66 is estimated at $1B annually in the U.S. MAY-44, which is being developed for the temporary relief of dyspareunia in breast cancer survivors and pre-menopausal and post-menopausal women. MAY-44 is protected by three issued patents and could become an FDA-approved topical non-estrogen-based product to address a market of as many as 34M American women for whom dyspareunia is common. The dyspareunia indication Mayfield will seek approval for is an estimated $2.1B annual U.S. market opportunity. MAY-88, which is a patent-pending oral suspension that Mayfield will develop for the treatment of moderate to severe interstitial cystitis. Mayfield believes the IC drug market, currently estimated at $400M annually, is highly underserved and in need of new treatment options for an estimated 8M U.S. patients who chronically suffer from IC. Mayfield's MAY-88 is initially pursuing an orphan population within the IC market.

07:45 EDT Theratechnologies to begin trading on Nasdaq Capital Market on Oct. 10 - Theratechnologies' common shares have been accepted for listing on the NASDAQ Capital Market and the common shares are expected to begin trading on such market on October 10, 2019 under the trading symbol "THTX".

07:39 EDT EbixCash signs multi-year agreements with travel exchanges - Ebix announced that its EbixCash Indian subsidiary has signed agreements with international travel exchanges to deliver millions of airline segments annually for a per segment fee, over a 5-year period, beginning immediately. As a part of this agreement, EbixCash collected a cumulative advance of $25M from the international travel exchanges. While the Company declined to disclose the details of the agreements for competitive reasons, EbixCash announced that over a period of time, it is targeting cumulative net annual revenues between $15M to $20M a year from international travel exchanges.

07:35 EDT Domino's Pizza CEO says Q3 a 'good quarter' - "It was a good quarter for Domino's, as we continue to lean on our fundamental strength against a unique competitive environment," said Ritch Allison, Domino's CEO. "Strong unit growth and positive comps yielded a solid and balanced quarter of retail sales growth across both the U.S. and international businesses. We remain steadfastly focused on driving profitable growth for the Domino's system, and most importantly, for our franchisees."

07:33 EDT Domino's Pizza announces new 2-3 year outlook - New 2-3 year outlook as follows: Global retail sales growth of 7%-10%; U.S. same store sales growth of 2%-5%; International same store sales growth of 1%-4%; Global net store growth of 6%-8%.

07:33 EDT Enlivex receives patent from European Patent Office covering Allocetra - Enlivex Therapeutics announced that the European Patent Office granted a new patent covering ALLOCETRA, the company's immunotherapy product. This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in the EU.

07:13 EDT Avrobio doses first patient in Phase 1/2 trial of gene therapy for cystinosis - Avrobio announced that the first patient has been dosed in the company's AVR-RD-04 investigational gene therapy program for cystinosis, a devastating lysosomal storage disease, in an ongoing Phase 1/2 clinical trial sponsored by academic collaborators at the University of California San Diego. The gene therapy is derived from the patient's own hematopoietic stem cells, which are genetically modified to produce functional cystinosin, a crucial protein that patients with cystinosis lack. The trial will enroll up to six patients with cystinosis, a rare inherited disease caused by a defect in the gene that encodes for cystinosin. The cystinosin protein enables transport of the amino acid cystine out of lysosomes. When it is absent, cystine accumulates and crystalizes, causing progressive damage to the kidneys, liver, muscles, eyes and other organs and tissues. Cystinosis affects both children and adults; they face shortened life spans and often painful symptoms, including muscle wasting, difficulty breathing, blindness and kidney failure.

07:12 EDT Valeritas announces presentation of preclinical h-Patch Apomorphine study - Valeritas Holdings announced a poster presentation at the 24th World Congress of Neurology held in Dubai, UAE/ On August 5th, Valeritas announced results from a preclinical pharmacokinetic study of continuous subcutaneous infusion of apomorphine delivered via its proprietary h-Patch wearable drug delivery device. The wearable h-Patch represents a patient-friendly subcutaneous delivery mechanism for Apo providing the benefits of a full 24-hour infusion of low dose Apo to eliminate "off" periods and improve motor status without tolerability issues seen with subcutaneous injections. Valeritas' h-Patch is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The company's V-Go is the first FDA-approved product that utilizes the h-Patch technology. To date, more than 20 million V-Go insulin delivery devices have been sold in the United States. Treatment of advanced Parkinson's disease remains challenging, with fluctuations in motor status often resulting in patients becoming severely handicapped. The magnitude and pattern of the motor response to a single dose of subcutaneously administered Apo are qualitatively comparable to that of oral levodopa; however, side effects of oral dosing can be problematic. Close to a dozen clinical studies have shown subcutaneous Apo infusions are successful in aborting "off" periods, reducing dyskinesias, and improving PD motor scores with the added benefit of a substantial levodopa-sparing effect. However, bulky infusion pumps requiring delivery of relatively large volumes of therapeutics remain a barrier to the development of therapeutic products that are patient and caregiver friendly.

07:07 EDT Plug Power, MULAG to bring ground support vehicles to Hamburg Airport - Plug Power has partnered with German specialty vehicle manufacturer MULAG to bring a new generation of hydrogen fuel cell-powered electric cargo tow tractors to Germany's Hamburg Airport. The two companies joined forces to build a fuel cell-powered vehicle, which ran alongside the airport's existing ground support equipment fleet for a period of evaluation and service testing, and concluded. The vehicle produced by the partnership was built by MULAG and operates using Plug Power's zero emission ProGen hydrogen engine. Based on its deployment and their scalability, Plug Power will provide Hamburg Airport with 60 additional units to power their baggage-towing fleet along with permanent hydrogen stations for consistent and efficient refueling.

07:03 EDT Trillium Therapeutics granted 180-day extension by Nasdaq to regain compliance - Trillium Therapeutics announced that it has received a notification letter from The Nasdaq Stock Market notifying the Company that it is eligible for an additional 180 calendar day period to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market. The notification has no immediate effect on the listing of the Company's common shares on the Exchange. The Company has an additional 180 calendar days from the date of notification, which occurred on October 3, 2019, or until March 30, 2020, to regain compliance with the minimum bid price requirement during which time the Company's common shares will continue to trade on the Exchange. If at any time before March 30, 2020 the bid price of the Company's common shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common shares between now and March 30, 2020, and intends to cure the deficiency within the additional period provided.

07:01 EDT iRadimed resolves warning letter related to infusion pump system - IRADIMED CORPORATION announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter. The Company does not expect a significant impact to its business or financial performance resulting from the close-out letter.

06:56 EDT Helen of Troy CEO says 'pleased' with Q2 performance - Julien Mininberg, CEO, stated: "We are pleased with our second quarter financial performance, which delivered consolidated core business sales growth of 5.7% and adjusted diluted EPS growth of 13.1%, both ahead of our expectations. During the quarter, we improved our consolidated operating margin, while simultaneously increasing our growth investments compared to our original outlook at the beginning of the year. These growth investments are generating healthy results and our digital initiatives continue to pay dividends, illustrated by online sales growth of 25%, which now represents 24% of total sales in the quarter. Consolidated sales growth was led by our Housewares segment as we expanded distribution and introduced new products that resonated well with both customers and consumers. Our Beauty segment continued to grow, driven by strong demand in the appliance category. Our Health & Home segment faced a particularly difficult comparison to the high base that included strong sales of seasonal products, distribution gains and significant international growth in the same period last year. Overall, a strong quarter and first half of our fiscal year." Mininberg continued: "Based on this performance and our expectations for the remainder of the fiscal year, we are pleased to raise our net sales and adjusted diluted EPS outlook for the full fiscal year 2020. We believe we are well positioned to continue driving meaningful long-term shareholder value as we execute our Phase II Transformation plan."

06:34 EDT Air Lease has commitments to acquire 318 new aircraft for delivery - Air Lease (AL) announced an update on activity taking place in the Q3. As of September 30 ALC's fleet was comprised of 307 owned aircraft and 64 managed aircraft. As of today, ALC has commitments to acquire a total of 318 new aircraft for delivery from Boeing (BA) and Airbus through 2024. Delivered 15 new aircraft including 2 Airbus A320neos, 6 Airbus A321neos, 1 Airbus A330-900neo, 1 Airbus A350-900, 2 Boeing 787-9s and 3 Boeing 787-10s. Aircraft investments in the quarter totaled approximately $1.5B. Completed the sale of 5 aircraft to a third-party buyer for sales proceeds of approximately $184M. Issued $1.1B in senior unsecured medium-term notes comprised of $600M due 2023 at a fixed rate of 2.25% and $500M due 2029 at a fixed rate of 3.25%

06:09 EDT PG&E may cut power for 600,000 customers due to wildfire risk - Based on current forecasted weather conditions, Pacific Gas and Electric Company said yesterday that it anticipates that it may begin implementing a Public Safety Power Shutoff to more than 600,000 customers across portions of nearly 30 northern, central, coastal and Bay Area counties. This would be a precautionary measure to reduce the risk of wildfire in these communities. If PG&E decides to implement a PSPS, the company expects to begin turning off power for safety early Wednesday morning. Based on the latest weather forecasts and models, PG&E anticipates the period of peak winds will occur from early Wednesday morning and last through Thursday midday. "This is shaping up to be one of the most severe dry wind events we've seen in our territory in recent years and we want our customers to be prepared for an extended outage that may last several days. Our meteorological and operations teams continue to actively monitor the weather and this evolving situation, and we are working directly with state and local agencies to help prepare our customers and the public for this safety event," said Michael Lewis, Senior Vice President, PG&E Electric Operations. "We want our customers to be aware that, based on this number, it could take several days to fully restore power after the weather passes and safety inspections are completed."

06:02 EDT Alio Gold signs lease agreement to acquire new loading and hauling equipment - Alio Gold announces the signing of lease agreements for the acquisition of new loading and hauling equipment at the Florida Canyon Mine. The fleet is comprised of thirteen 90-tonne haul trucks and three matched front-end loaders. The lease agreements and accompanying maintenance contract are for an approximate five-year term, depending on the actual hours of operation, after which the equipment can be purchased for approximately $2M. The existing fleet will be retired as the new fleet becomes operational. Florida Canyon is well advanced on commissioning the new fleet with four trucks and one loader currently production ready; five additional trucks and one loader are currently on site in various stages of assembly; and the remaining four trucks and loader are due for delivery in October.

05:25 EDT Prevail Therapeutics enters strategic collaboration with Lonza - Prevail Therapeutics and Lonza announced that the companies have entered into a strategic collaboration. Lonza and Prevail have been working together since 2018, with an initial focus on process development, towards the GMP manufacturing of Prevail's two lead programs, PR001 and PR006. Under this collaboration, focused on the baculovirus/Sf9 production system for gene therapies, Lonza will manufacture Prevail's pipeline of novel AAV-based gene therapy programs for patients with neurodegenerative diseases at its gene therapy center of excellence in Houston, TX.

05:10 EDT Asure Software sells Workspace Management business to FM:Systems for $120M - Asure Software announced that it has entered into an agreement to sell its Workspace Management business to FM:Systems in an asset and equity transaction valued at $120M. This transaction enables Asure to focus on and continue to deliver its award-winning Human Capital Management solutions to small and midsize businesses. The transaction is expected to close in approximately 45 to 60 days, subject to customary closing conditions.